Eli Lilly and Company

Company Profile

Eli Lilly and Company had its IPO on 1978-01-13 under the ticker symbol LLY.

The company operates in the Healthcare sector and Drug Manufacturers-General industry. Eli Lilly and Company has a staff strength of 39,000 employees.

Stock update

Shares of Eli Lilly and Company opened at $590.97 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $587.85 - $601.13, and closed at $599.3.

This is a +0.63% increase from the previous day's closing price.

A total volume of 2,899,998 shares were traded at the close of the day’s session.

In the last one week, shares of Eli Lilly and Company have increased by +7.57%.

Eli Lilly and Company's Key Ratios

Eli Lilly and Company has a market cap of $565.36 billion, indicating a price to book ratio of 34.0617 and a price to sales ratio of 11.699.

In the last 12-months Eli Lilly and Company’s revenue was $29.52 billion with a gross profit of $21.91 billion and an EBITDA of $9.77 billion. The EBITDA ratio measures Eli Lilly and Company's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Eli Lilly and Company’s operating margin was 28.12% while its return on assets stood at 10.18% with a return of equity of 65.6%.

In Q2, Eli Lilly and Company’s quarterly earnings growth was a positive 85.7% while revenue growth was a positive 28.1%.

Eli Lilly and Company’s PE and PEG Ratio

Forward PE

39.0625

Trailing PE

82.6019

PEG

2.1814

Its diluted EPS in the last 12-months stands at $7.21 per share while it has a forward price to earnings multiple of 39.0625 and a PEG multiple of 2.1814. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eli Lilly and Company’s profitability.

Eli Lilly and Company stock is trading at a EV to sales ratio of 12.1805 and a EV to EBITDA ratio of 42.0381. Its price to sales ratio in the trailing 12-months stood at 11.699.

Eli Lilly and Company stock pays annual dividends of $4.22 per share, indicating a yield of 0.76% and a payout ratio of 56.03%.

Balance sheet and cash flow metrics

Total Assets

$54.81 billion

Total Liabilities

$18.92 billion

Operating Cash Flow

$-459100000.00

Capital Expenditure

$836.30 million

Dividend Payout Ratio

56.03%

Eli Lilly and Company ended 2024 with $54.81 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $54.81 billion while shareholder equity stood at $11.06 billion.

Eli Lilly and Company ended 2024 with $0 in deferred long-term liabilities, $18.92 billion in other current liabilities, 593600000.00 in common stock, $10.37 billion in retained earnings and $4.08 billion in goodwill. Its cash balance stood at $2.69 billion and cash and short-term investments were $2.83 billion. The company’s total short-term debt was $661,600,000 while long-term debt stood at $18.16 billion.

Eli Lilly and Company’s total current assets stands at $21.33 billion while long-term investments were $2.75 billion and short-term investments were $134.60 million. Its net receivables were $9.17 billion compared to accounts payable of $2.47 billion and inventory worth $4.80 billion.

In 2024, Eli Lilly and Company's operating cash flow was $-459100000.00 while its capital expenditure stood at $836.30 million.

Comparatively, Eli Lilly and Company paid $0.56 in dividends in 2024.

Other key metrics

Current Trading Price

$599.3

52-Week High

$601.13

52-Week Low

$293.1866

Analyst Target Price

$546.68

Eli Lilly and Company stock is currently trading at $599.3 per share. It touched a 52-week high of $601.13 and a 52-week low of $601.13. Analysts tracking the stock have a 12-month average target price of $546.68.

Its 50-day moving average was $502.37 and 200-day moving average was $406.23 The short ratio stood at 1.68 indicating a short percent outstanding of 0%.

Around 15.3% of the company’s stock are held by insiders while 8398.5% are held by institutions.